| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Odiparcil targets glycosaminoglycan synthesis or function, acting as a glycosaminoglycan enhancer. As a beta-D-thioxyloside analog, it modulates the biosynthesis of glycosaminoglycans, which are involved in hemostasis and thrombosis. The compound's antithrombotic activity is associated with a reduced risk of bleeding compared to conventional anticoagulants.
|
|---|---|
| ln Vitro |
In vitro, Odiparcil acts as a beta-D-thioxyloside analog with antithrombotic activity. Its activity is assessed by measuring its effects on glycosaminoglycan synthesis and thrombus formation in vitro. The compound's reduced bleeding risk relative to other antithrombotics is an important aspect of its profile.
|
| ln Vivo |
In vivo activity of Odiparcil has been demonstrated in animal models of thrombosis. As an orally active compound, it is suitable for oral administration. Its in vivo efficacy is assessed by measuring inhibition of thrombus formation, bleeding time, and other hemostatic parameters.
|
| Enzyme Assay |
Cell-free assays for Odiparcil involve studying its effects on glycosaminoglycan biosynthesis using biochemical assays. These assays may use purified enzymes involved in glycosaminoglycan synthesis or cell extracts to measure the compound's effects on the production of glycosaminoglycans.
|
| Cell Assay |
In vitro cellular assays for Odiparcil are performed using cells that synthesize glycosaminoglycans, such as chondrocytes or vascular cells. These assays measure the compound's ability to modulate glycosaminoglycan production and its effects on cellular functions related to hemostasis and thrombosis.
|
| Animal Protocol |
In vivo animal studies for Odiparcil are conducted in models of thrombosis, such as the rat or rabbit thrombosis models. These studies typically involve oral administration of the compound, followed by assessment of thrombus formation, bleeding time, and coagulation parameters. The compound's reduced bleeding risk is evaluated in these models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Odiparcil are characterized by oral bioavailability. The compound has a molecular formula of C₁₅H₁₆O₆S and a molecular weight of 324.35 g/mol. Its chemical name is 4-methyl-7-(5-thio-β-D-xylopyranosyloxy)-2H-chromen-2-one. Its pharmacokinetic profile supports oral dosing for antithrombotic indications.
|
| Toxicity/Toxicokinetics |
Toxicology studies of Odiparcil have been conducted to support its development as an antithrombotic agent. As an antithrombotic, its toxicology profile includes effects on hemostasis and bleeding risk. The compound's reduced risk of adverse bleeding events compared to conventional anticoagulants is an important aspect of its safety profile.
|
| References |
|
| Additional Infomation |
Drug Indication
This drug has been studied for the treatment of atrial fibrillation, cardiovascular disease, thrombosis, and venous thromboembolism. Odiparcil (CAS: 137215-12-4) is a novel, orally active beta-D-thioxyloside analog with antithrombotic activity. It has the INN name Odiparcil and is an antithrombotic agent. The compound has a molecular formula of C₁₅H₁₆O₆S and a molecular weight of 324.35 g/mol. It is for research use only. |
| Molecular Formula |
C15H16O6S
|
|---|---|
| Molecular Weight |
324.3489
|
| Exact Mass |
324.067
|
| CAS # |
137215-12-4
|
| PubChem CID |
216385
|
| Appearance |
White to off-white solid powder
|
| Vapour Pressure |
1.03E-13mmHg at 25°C
|
| LogP |
0.635
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
467
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H](CS3)O)O)O
|
| InChi Key |
JRHNIQQUVJOPQC-AQNFWKISSA-N
|
| InChi Code |
InChI=1S/C15H16O6S/c1-7-4-12(17)21-11-5-8(2-3-9(7)11)20-15-14(19)13(18)10(16)6-22-15/h2-5,10,13-16,18-19H,6H2,1H3/t10-,13+,14-,15-/m1/s1
|
| Chemical Name |
4-methyl-7-[(2R,3R,4S,5S)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one
|
| Synonyms |
Odiparcil; GSK424323 GSK 424323; GSK-424323
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~308.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0831 mL | 15.4154 mL | 30.8309 mL | |
| 5 mM | 0.6166 mL | 3.0831 mL | 6.1662 mL | |
| 10 mM | 0.3083 mL | 1.5415 mL | 3.0831 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
